Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03873610 · ClinicalTrials.gov registry record · NA
Resiliency Training in Adolescents With NF1 and NF2
A NA study of Neurofibromatoses, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT03873610 is a NA study of Neurofibromatoses that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03873610, a NA study of Neurofibromatoses, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized controlled trial for resiliency training in adolescents with Neurofibromatosis 1 and Neurofibromatosis 2 via secure live video to determine the efficacy two stress and symptom management programs. Both programs are 8 week group programs.
Conditions Studied
Interventions
- BEHAVIORAL Stress and Symptom Management Program 1
- BEHAVIORAL Stress and Symptom Management Program 2
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-12-15 |
| Est. Completion | 2026-02-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03873610
The ClinicalTrials.gov registry entry for NCT03873610 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurofibromatoses appearing as the primary indexed condition, and to 2 interventions - of which Stress and Symptom Management Program 1 is the first listed.
NCT03873610 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03873610 about?
NCT03873610 is a clinical study titled "Resiliency Training in Adolescents With NF1 and NF2". This randomized controlled trial for resiliency training in adolescents with Neurofibromatosis 1 and Neurofibromatosis 2 via secure live video to determine the efficacy two stress and symptom management programs. Both programs are 8 week group programs.
What is the current status of trial NCT03873610?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2019-12-15. Estimated completion is 2026-02-20.
What conditions does trial NCT03873610 study?
This clinical trial studies the following conditions: Neurofibromatoses.
What interventions are being tested in trial NCT03873610?
The interventions under investigation include: Stress and Symptom Management Program 1 (BEHAVIORAL), Stress and Symptom Management Program 2 (BEHAVIORAL).
Who is sponsoring clinical trial NCT03873610?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03873610 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatoses
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.